Barragán-Pérez E, Garza-Peña A, Benavides-Guerrero O, Hernández-Aguilar J

Language: Spanish
References: 13
Page: 421-427
PDF size: 81.17 Kb.

ABSTRACT

Introduction. Disruptive behavior (DB) is frequent in pediatric patients with epilepsy.This conducts impacts on the functioning of the children, and often leads to their social rejection. The objectives of this study were to observe the efficacy and safety of risperidone in the treatment of acute disruptive behavior in pediatric patients with epilepsy.
Material and methods. A clinical open label, prospective study with a month follow up was carried out. Pediatric patients with epilepsy (partial or generalized) and disruptive behavior, both gender, between 5 and 14 years of age seen in the neurology department, Hospital Infantil de Mexico,were enrolled.The efficacy was evaluated with CGI, Peers scale and ADHD RS. Number of seizures and secondary effects was evaluated with the same methods.
Results. A total of 23 patients, 7 females and 16 males enter the study with a relation M:F of 1.5:1. All the patients had epilepsy, either partial or generalized. The average doses of risperidone was 0.75 mg/kg/d, with and efficacy of 91% at the final of the 4 weeks follow up.The more frequent side effects were increase in weight in 12 patients, extrapiramidal symptoms (head and neck discinesias) sialorrhea, thirst and somnolence.
Conclusions. With these results, we support in this clinic open label study, the efficacy and safety of the use of risperidone in the management of acute disruptive behaviors in pediatric patients with epilepsy.

REFERENCES

1. Pellock JM. Managing pediatric epilepsy syndrome with new antiepileptic drugs. Pediatrics. 1999; 104: 630-3.

2. Zupanc ML. Update on epilepsy in pediatric patients. Mayo Clin Proc. 1996; 71: 899-916.

3. Barragán E. Daño neurológico y epilepsia: Estrategia y herramientas multidisciplinarias de apoyo. 2da. ed. México, D. F.: Editorial Linae; 2004.

4. McCkacken JT, McGough J, Shah B. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347: 314-21.

5. Treatment with atypical antipsychotics: new indications and new populations (Review). J Psyc Res. 2001; 35: 187-91.

6. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002; 110: e34.

7. Gonzalez-Heydrich J, Pandina GJ, Fleischer CA. No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. J Child Adolesc Psychophar. 2004; 14: 295-310.

8. Barnard L, Young AH, Pearson J, Geddes J, O^Brien G. A systemic review of the use of atypical antipsychotics in autism. J Psychophar. 2002; 16: 93-101.

9. Simeon J, Milin R, Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders (Review). Progress in Neuro-Psychophar Biol Psychiatr. 2002; 26: 267-75.

10. Walker S. Effects of risperidone on aberrant behaviour of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Men Retard. 2001; 106: 525-38.

11. Silver JF, Sander H. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta analysis of controlled trials. Europ Neuro Psychophar. 2001; 11: 289-93.

12. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharma. 2001; 11: 229-38.

13. Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psych. 2001; 62: 114-6.